text_1: Combining phosphatidylinositide 3-kinase and MEK 1/2 inhibitors is effective at treating KRAS mutant tumors.
text_2: They are most frequently observed in two hotspots: the helical domain (E545K and E542K) and the kinase domain (H1047R).